What lessons can be learnt from treating Trump? Why is his proclamation of Regeneron's unproven and experimental antibody ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...

Moving to our Regeneron genetics medicine pipeline. Starting with our differentiated siRNA plus antibody approach, we have the potential to address multiple complement mediated diseases.

Regeneron’s antibody cocktail is the latest COVID-19 drug to receive Emergency Use Authorization in the US, becoming the first therapy of this kind to become available.

Scientists from Regeneron selected the two most potent, non-competing virus-neutralising antibodies and scaled up production to create the REGN-COV2 cocktail. REGN-COV2's two antibodies bind ...

Elsewhere within Regeneron's product portfolio, Libtayo, a programmed death receptor-1 (PD-1) blocking antibody indicated for non-small cell lung cancer ("NSCLC"), cutaneous squamous cell ...

According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent ...

Jan 22 (Reuters) - (This is an excerpt of the Health Rounds newsletter, where we present latest medical studies on Tuesdays and Thursdays. To receive the full newsletter in your inbox for free ...

“We purchased Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), a biopharmaceutical company that was built on a foundation in basic scientific research and antibody development. The company has ...

Regeneron also resubmitted the BLA for odronextamab, a bispecific antibody targeting CD20 and CD3, in R/R follicular lymphoma, to the FDA. The EC also approved Kevzara (sarilumab) for the ...

Regeneron Pharmaceuticals (Nasdaq ... Full year 2024 revenues increased 8% to $14.20 billion versus 2023; excluding Covid antibody treatment Ronapreve (casirivimab and imdevimab) revenues increased 10 ...